Here's a look at some of the top Wall Street stories for medical device companies this week: Abbott may look to expand medical device business footprint; Device makers take big writedowns on renal denervation; Cardinal Health closes $320M AccessClosure buy; K2M prices IPO under range at $132M; Allergan board spurns Valeant's $47B offer.
Access Closure Inc.
, Boston Scientific
, Cardinal Health
, Pershing Capital Management
, St. Jude Medical
, Valeant Pharmaceuticals
, Abbott Laboratories
, Allergan Inc.
Boston Scientific, Medtronic and Covidien take millions in write-downs on their renal denervation assets after the failure of Medtronic's Symplicity-3 trial.
MobiHealthNews reports that medtech titan Covidien acquired Zephyr Technology, maker of wireless patient monitors.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
Medtech giant Covidien posts modest top and bottom-line gains for its 1st quarter following the $860 million acquisition of Given Imaging.
Ireland-based medtech maker Covidien (NYSE:COV) posted the results from its latest quarter, spurring a 2.2% drop in the company's shares.
The FDA slaps Covidien's recall of its Pipeline and Alligator brain aneurysm devices with Class I status, denoting the potential for serious injury or death.
The FDA today gave the recall by Covidien (NYSE:COV) of some of its Pipeline and Alligator brain aneurysm devices earlier this month Class I status, its most serious recall category.
Covidien touts FDA clearance for its novel camera-equipped Kangaroo feeding tube designed to provide visualization for an otherwise blind procedure.
Medtech titan Covidien (NYSE:COV) received FDA clearance for its visual Kangaroo feeding tube, equipped with an endoscopic camera that allows physicians to see into the procedure in a new way.